LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$1.45
-0.10 (-6.45%)
Open$1.55
Previous Close$1.55
Day High$1.55
Day Low$1.44
52W High$2.09
52W Low$0.37
Volume—
Avg Volume1.33M
Market Cap386.09M
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,687.6% upside
Current
$1.45
$1.45
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 15.27M | 15.33M | 231.61M |
| Net Income | -66,623,906 | -60,160,043 | -65,233,876 |
| Profit Margin | -436.5% | -414.7% | -28.2% |
| EBITDA | -75,286,703 | -71,759,173 | -95,106,936 |
| Free Cash Flow | — | — | -33,113,271 |
| Rev Growth | -0.3% | -0.3% | -6.2% |
| Debt/Equity | 0.00 | 0.00 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |